Pharmaceutical Executive April 2014

April 2014 | Volume 0, Issue 0
Features
Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
By Pharmaceutical Executive Editors
California's Bay Area and the Boston/Cambridge nexus continue to dominate bioinnovation in the US. Pharm Exec looks at the factors contributing to the strategic dominance of these regions.
The Healthcare Businesswomen's Association honored three female leaders this year. We take an in-depth look at each winner's background and career—and what factors helped push them to the top of their game.
From the Editor
Three examples from Pharm Exec's coverage this month show that, in our industry, there are always two sides—at least—to every question.
Column
Ben Comer reports on how new pipeline therapies, public research investments, and a renewed sociopolitical focus are working toward a happier outcome for sickle cell disease patients.
Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.
The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
By Pharmaceutical Executive Editors
Three strategic implications for pharma pricing strategies in India.
native1_300x100
lorem ipsum